FLOW (trial)

The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.

Definition

First GLP-1 trial dedicated to chronic kidney disease outcomes. N=3,533 adults with type 2 diabetes + CKD, randomized to semaglutide 1 mg vs placebo (Perkovic 2024 NEJM, PMID 38785209). Primary kidney composite reduced 24% (HR 0.76). Stopped early for efficacy. Drove the January 2025 FDA Ozempic label expansion for kidney-disease progression prevention.

FLOW trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Major trials

STEP-1
SURMOUNT-1
SELECT
FLOW
SURMOUNT-OSA
STEP-TEENS
MACE (Major Adverse Cardiovascular Events)
KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — Clinical Summary Score)
ATTAIN-1
IWQOL-Lite-CT
STEP-4 (withdrawal trial)
SYNERGY-NASH
LEADER (trial)

Looking for more depth?

FLOW trial deep-dive
Browse the full GLP-1 glossary (124 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers